RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved agent-like properties, with an IC50 of 63.8 nM[1].
RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM[1].
RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3 μM in Th17 cell differentiation assay[1].
RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model[1].
RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model[1].
| Animal Model: | Imiquimod (IMQ)-induced psoriasis mice model[1]. |
| Dosage: | 25 mg/kg. |
| Administration: | Orally, twice daily. |
| Result: | Brought in a significant reduction in clinical severity of psoriasis as measured through the ear erythema, back skin erythema and scaliness scales. |
| Animal Model: | Male CD-1 Mice[1]. |
| Dosage: | 1 mg/kg (i.v.) and 5 mg/kg (p.o.)(Pharmacokinetic Analysis). |
| Administration: | IV or PO, single dose. |
| Result: | Cmax: 609.67 ng/mL (PO), 1550 ng/mL (IV).
T1/2: 3.63 h (PO), 3.04 h (IV).
|
[1]. Nannan Sun, et al. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists. Eur J Med Chem. 2020 Jul 5;202:112536.